Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Parallel Group Study to Assess the Inhibition of Brain MAO-B by RO4602522 After Repeated Dosing in Patients With Alzheimer's Disease and in Healthy Control Subjects

NCT01701089 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01701089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01701089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Parallel Group Study to Assess the Inhibition of Brain MAO-B by RO4602522 After Repeated Dosing in Patients With Alzheimer's Disease and in Healthy Control Subjects
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2012
Completion date
May 31, 2013
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer, alzheimer's disease